Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra

Abstract

Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contraThe review presents the results of a combined analysis of literature data and own clinical observations regarding the safety and feasibility of using monoclonal anti-CD20 antibodies in the treatment of B-cell lymphoproliferative diseases during the COVID-19 pandemic. The main points of the pathogenesis of the influence of monoclonal anti-CD20 antibodies on the course of COVID-19 are described. The current trends in the modification of the accepted algorithms of lymphoproliferative diseases therapy with the inclusion of monoclonal anti-CD20 antibodies are summarized, and the possibilities of specific prevention by vaccination against COVID-19 are also considered.

Keywords

• monoclonal anti-cd20 antibody
• rituximab
• obinutuzumab
• new coronavirus infection covid-19
• lymphoproliferative disease
• b-cell non-hodgkin lymphoma
• vaccination